FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136458548> ?p ?o ?g. }

• W3136458548 endingPage "101" @default.
• W3136458548 startingPage "93" @default.
• W3136458548 abstract "In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates. Anthracycline-free NACT regimens avoid toxicities associated with anthracyclines, but every 3-week TCHP also has substantial side effects. We hypothesized that a weekly regimen might have equivalent efficacy with less toxicity; we also investigated whether poorly responding patients would benefit from switching to AC.Patients with clinical stage II-III HER2+ BC received weekly paclitaxel 80 mg/m2 and carboplatin AUC2 with every 3-week trastuzumab and pertuzumab (wPCbTP), with the option of splitting the pertuzumab loading dose. After 12 weeks, responding patients continued wPCbTP for another 6 weeks, while non-responders switched to AC. Dose modifications and post-op therapy were at investigator discretion.In 30 evaluable patients, the pCR rate was 77% (95% CI 58-90%); 12/14 (86%) in ER-negative and 11/16 (69%) in ER-positive. Only two patients transitioned to AC for non-response, of which one achieved pCR. There were no episodes of febrile neutropenia or grade ≥ 3 peripheral neuropathy, though several patients who continued wPCbTP stopped before week 18. Split-dose pertuzumab was associated with less grade ≥ 2 diarrhea (40%) than the standard loading dose (60%).pCR rates with our regimen were as high as reported with TCHP with fewer grade ≥ 3 toxicities, though diarrhea remains a concern. Too few patients had a suboptimal response to adequately test switching to AC. The wPCbTP regimen should be considered an alternative to TCHP as neoadjuvant therapy for HER2+ BC.ClinicalTrials.gov identifier: NCT02789657." @default.
• W3136458548 created "2021-03-29" @default.
• W3136458548 creator A5004476044 @default.
• W3136458548 creator A5015862083 @default.
• W3136458548 creator A5028440343 @default.
• W3136458548 creator A5045617170 @default.
• W3136458548 creator A5054730388 @default.
• W3136458548 creator A5057688582 @default.
• W3136458548 creator A5058210944 @default.
• W3136458548 creator A5066901675 @default.
• W3136458548 creator A5067710631 @default.
• W3136458548 creator A5071992422 @default.
• W3136458548 creator A5073112596 @default.
• W3136458548 creator A5073527533 @default.
• W3136458548 creator A5073834752 @default.
• W3136458548 creator A5076176692 @default.
• W3136458548 creator A5080157873 @default.
• W3136458548 creator A5082664275 @default.
• W3136458548 creator A5088322684 @default.
• W3136458548 date "2021-06-04" @default.
• W3136458548 modified "2023-10-01" @default.
• W3136458548 title "Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study" @default.
• W3136458548 cites W1977433804 @default.
• W3136458548 cites W2026981776 @default.
• W3136458548 cites W2075894019 @default.
• W3136458548 cites W2086064725 @default.
• W3136458548 cites W2095861620 @default.
• W3136458548 cites W2096145980 @default.
• W3136458548 cites W2098775844 @default.
• W3136458548 cites W2148962667 @default.
• W3136458548 cites W2149719146 @default.
• W3136458548 cites W2264815585 @default.
• W3136458548 cites W2768649895 @default.
• W3136458548 cites W2774227900 @default.
• W3136458548 cites W2899659781 @default.
• W3136458548 cites W2902218997 @default.
• W3136458548 cites W3006134372 @default.
• W3136458548 cites W3031350720 @default.
• W3136458548 doi "https://doi.org/10.1007/s10549-021-06266-9" @default.
• W3136458548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34086171" @default.
• W3136458548 hasPublicationYear "2021" @default.
• W3136458548 type Work @default.
• W3136458548 sameAs 3136458548 @default.
• W3136458548 citedByCount "1" @default.
• W3136458548 countsByYear W31364585482021 @default.
• W3136458548 crossrefType "journal-article" @default.
• W3136458548 hasAuthorship W3136458548A5004476044 @default.
• W3136458548 hasAuthorship W3136458548A5015862083 @default.
• W3136458548 hasAuthorship W3136458548A5028440343 @default.
• W3136458548 hasAuthorship W3136458548A5045617170 @default.
• W3136458548 hasAuthorship W3136458548A5054730388 @default.
• W3136458548 hasAuthorship W3136458548A5057688582 @default.
• W3136458548 hasAuthorship W3136458548A5058210944 @default.
• W3136458548 hasAuthorship W3136458548A5066901675 @default.
• W3136458548 hasAuthorship W3136458548A5067710631 @default.
• W3136458548 hasAuthorship W3136458548A5071992422 @default.
• W3136458548 hasAuthorship W3136458548A5073112596 @default.
• W3136458548 hasAuthorship W3136458548A5073527533 @default.
• W3136458548 hasAuthorship W3136458548A5073834752 @default.
• W3136458548 hasAuthorship W3136458548A5076176692 @default.
• W3136458548 hasAuthorship W3136458548A5080157873 @default.
• W3136458548 hasAuthorship W3136458548A5082664275 @default.
• W3136458548 hasAuthorship W3136458548A5088322684 @default.
• W3136458548 hasBestOaLocation W31364585482 @default.
• W3136458548 hasConcept C121608353 @default.
• W3136458548 hasConcept C126322002 @default.
• W3136458548 hasConcept C143998085 @default.
• W3136458548 hasConcept C2776694085 @default.
• W3136458548 hasConcept C2776802502 @default.
• W3136458548 hasConcept C2777063308 @default.
• W3136458548 hasConcept C2777511904 @default.
• W3136458548 hasConcept C2778239845 @default.
• W3136458548 hasConcept C2778292576 @default.
• W3136458548 hasConcept C2778850193 @default.
• W3136458548 hasConcept C2779786085 @default.
• W3136458548 hasConcept C2781164504 @default.
• W3136458548 hasConcept C2781413609 @default.
• W3136458548 hasConcept C2781451048 @default.
• W3136458548 hasConcept C530470458 @default.
• W3136458548 hasConcept C71924100 @default.
• W3136458548 hasConcept C90924648 @default.
• W3136458548 hasConceptScore W3136458548C121608353 @default.
• W3136458548 hasConceptScore W3136458548C126322002 @default.
• W3136458548 hasConceptScore W3136458548C143998085 @default.
• W3136458548 hasConceptScore W3136458548C2776694085 @default.
• W3136458548 hasConceptScore W3136458548C2776802502 @default.
• W3136458548 hasConceptScore W3136458548C2777063308 @default.
• W3136458548 hasConceptScore W3136458548C2777511904 @default.
• W3136458548 hasConceptScore W3136458548C2778239845 @default.
• W3136458548 hasConceptScore W3136458548C2778292576 @default.
• W3136458548 hasConceptScore W3136458548C2778850193 @default.
• W3136458548 hasConceptScore W3136458548C2779786085 @default.
• W3136458548 hasConceptScore W3136458548C2781164504 @default.
• W3136458548 hasConceptScore W3136458548C2781413609 @default.
• W3136458548 hasConceptScore W3136458548C2781451048 @default.
• W3136458548 hasConceptScore W3136458548C530470458 @default.
• W3136458548 hasConceptScore W3136458548C71924100 @default.
• W3136458548 hasConceptScore W3136458548C90924648 @default.

• next